Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Gastric MALT-lymphoma and Helicobacter pylori infection Bayerdorffer E; Miehlke S; Neubauer A; Stolte MAliment Pharmacol Ther 1997[Apr]; 11 Suppl 1 (ä): 89-94The presence of lymphoid tissue in the gastric mucosa is virtually pathognomonic of Helicobacter pylori infection. This lymphoid tissue has mucosa-associated lymphoid tissue (MALT) characteristics suggesting that H. pylori infection may represent a stimulus for the growth of gastric MALT lymphoma. H. pylori can be detected in more than 90% of patients with low-grade gastric MALT lymphoma supporting the aetiological role of the organism. The strongest evidence for the significance of H. pylori in the pathogenesis of low aetological-grade gastric MALT lymphoma is provided by clinical studies showing that cure of H. pylori infection is followed by a complete regression of these tumours in most patients. This paper reviews the current knowledge about antibacterial treatment of low-grade gastric MALT lymphoma, and immunological and molecular aspects in the pathogenesis of the disease.|Anti-Bacterial Agents/administration & dosage/pharmacology/*therapeutic use[MESH]|Cell Division[MESH]|Clinical Trials as Topic[MESH]|Follow-Up Studies[MESH]|Helicobacter Infections/*complications/drug therapy/physiopathology[MESH]|Helicobacter pylori/drug effects/*physiology[MESH]|Humans[MESH]|Lymphoma, B-Cell, Marginal Zone/drug therapy/epidemiology/*microbiology[MESH]|Lymphoma/classification[MESH]|Treatment Outcome[MESH] |
